索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效评价  

Virological response of patients with chronic hepatitis C to sofebuvir and redipavir combination regimen treatment

作　　者：黎防 杨宏飞 张青[1] Li Fang;Yang Hongfei;Zhang Qing(Department of Liver disease,Fourth People's Hospital,Huai'an 223000,Jiangsu Province,China)

机构地区：[1]江苏省淮安市第四人民医院肝病科,223000 [2]东南大学中大医院江北院区心血管内科

出　　处：《实用肝脏病杂志》2024年第5期685-688,共4页Journal of Practical Hepatology

基　　金：江苏省自然科学基金青年基金资助项目(编号:SBK2020040678)。

摘　　要：目的探讨索非布韦联合雷迪帕韦治疗慢性丙型肝炎(CHC)患者的疗效和安全性。方法2017年2月~2023年3月我院诊治的CHC患者48例,被随机分为观察组24例,给予索非布韦联合雷迪帕韦治疗12 w,和对照组24例,给予聚乙二醇干扰素-α联合利巴韦林治疗24 w。评估快速病毒学应答(RVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)。结果观察组RVR、ETVR和SVR分别为75.0%、95.8%和95.8%,均显著高于对照组的58.3%、70.8%和66.7%(P<0.05);在治疗结束时,观察组外周血PLT和WBC计数分别为(201.5±22.3)×109/L和(6.5±1.4)×10^(9)/L,均显著大于对照组【分别为(137.6±15.0)×10^(9)/L和(3.7±1.3)×10^(9)/L,P<0.05】,血清ALT水平为(36.2±4.3)U/L,显著低于对照组【(60.8±5.4)U/L,P<0.05】;在治疗过程中,干扰素-α治疗组出现发热20例(83.3%)、粒细胞减少15例(62.5%)和PLT减少10例(41.7%)。结论应用索非布韦联合雷迪帕韦治疗CHC患者疗效好,不良反应少,值得扩大应用,而尽可能减少α-干扰素类继续治疗CHC患者。Objective This clinical trial was conducted to investigate efficacy and safety of sofebuvir and redipavir combination in the treatment of patients with chronic hepatitis C(CHC).Methods Forty-eight patients with CHC were enrolled in our hospital between February 2017 and March 2023,and were randomly divided into observation(n=24)and control group(n=24),receiving sofebuvir and redipavir combination for 12 weeks or peginterferon-αand ribavirin combination for 24 weeks,respectively.Rapid virological response(RVR),end of treatment(EOT)virological response(ETVR)and sustained virological response(SVR)were recorded.Results The clinical materials including HCV genotypes at baseline in the two groups were comparable(P>0.05);RVR,ETVR and SVR in the DAA-treated patients were 75.0%,95.8%and 95.8%,all much higher than 58.3%,70.8%and 66.7%(P<0.05)in peginterferon-α-treated patients;by end of antiviral treatment,platelet and white blood cell counts in DAA-treated patients were(201.5±22.3)×10^(9)/L and(6.5±1.4)×10^(9)/L,both significantly higher than[(137.6±15.0)×10^(9)/L and(3.7±1.3)×10^(9)/L,P<0.05],while serum ALT level was(36.2±4.3)U/L,much lower than[(60.8±5.4)U/L,P<0.05]in peginterferon-α-treated patients;during antiviral treatment,adverse events rates,such as fever occurred in 83.3%,granulocytopenia in 62.5%and thrombocytopenia in 41.7%in peginterferon-α-treated patients.Conclusion Sofebuvir and redipavir combination therapy in treatment of patients with CHC has a satisfactory efficacy and relatively less adverse events,which warrants widespread clinical application.

关 键 词：慢性丙型肝炎 索非布韦 雷迪帕韦 治疗 

分 类 号：R512.63[医药卫生—内科学]